Dominik Chraniuk

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study

Meletios Α. Dimopoulos, Vânia Hungria, Atanas Radinoff et al. · The Lancet Haematology · 2023 · 113 citations

Hematological Malignancy, Oncology, Metronomic Therapy +10

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk et al. · Blood · 2023 · 28 citations

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial

Raajit K. Rampal, Sebastian Grosicki, Dominik Chraniuk et al. · Nature Medicine · 2025 · 16 citations · Full text

Identification of miRSNPs associated with the risk of multiple myeloma

Angelica Macauda, Diego Calvetti, Giuseppe Maccari et al. · International Journal of Cancer · 2016 · 12 citations · Full text